Abstract Title

Atrophied thymus can serve as a tumor reservoir for harboring melanoma cells

Presenter Name

Olga Sizova

RAD Assignment Number

1303

Abstract

Purpose: Tumor metastatic relapse is responsible for main cancer associated mortality and potentially arises from the undetectable minimal number of tumor cells, which are able to resist radio-chemotherapy at a dormant state hiding in certain organs (termed: tumor reservoirs). The largest T-lymphoid organ, the thymus, has been suggested as this kind of pre-metastatic tumor reservoir for B-lymphoma cells. It remains unknown whether the thymus is able to harbor non-lymphoid solid tumor cells, why chemotherapy cannot thoroughly eliminate cancer cells in the thymus, and what the state of thymic occult cancer cells is during chemotherapy.

Methods: With melanoma inoculated and genotoxic doxorubicin (Doxo) treated mouse model, we determined that the thymus, particularly the atrophied thymus, was able to harbor blood stream-circulating melanoma cells. Using specific in vivo + in vitro technique, where thymuses of doxorubicin- or PBS-treated mice are co-cultured with doxorubicin-treated melanoma cells in trans-well system we want to provide the insight of the changes in the status of cancer cells.

Results: We found that chemotherapy-resulted DNA-damage response triggered p53 activation in non-malignant thymic cells, which in turn resulted in thymocyte death and thymic epithelial cell senescence to develop an inflammatory thymic microenvironment. Co-culture of PBS- or Doxo- treated thymus with Doxo-treated melanoma cells provides evidence that chemotherapy-altered inflammatory thymic microenvironment protects cancer cells from apoptosis via induction of dormancy.

Conclusion: Therefore, the thymus, which becomes a pre-metastatic reservoir for non-lymphoid solid tumor cells under chemotherapy, should be a novel target in antitumor therapy for considering and preventing from tumor metastatic relapse.

Is your abstract for competition or not for competition?

Competition

Research Area

Immunology

Presentation Type

Oral

This document is currently not available here.

Share

COinS
 

Atrophied thymus can serve as a tumor reservoir for harboring melanoma cells

Purpose: Tumor metastatic relapse is responsible for main cancer associated mortality and potentially arises from the undetectable minimal number of tumor cells, which are able to resist radio-chemotherapy at a dormant state hiding in certain organs (termed: tumor reservoirs). The largest T-lymphoid organ, the thymus, has been suggested as this kind of pre-metastatic tumor reservoir for B-lymphoma cells. It remains unknown whether the thymus is able to harbor non-lymphoid solid tumor cells, why chemotherapy cannot thoroughly eliminate cancer cells in the thymus, and what the state of thymic occult cancer cells is during chemotherapy.

Methods: With melanoma inoculated and genotoxic doxorubicin (Doxo) treated mouse model, we determined that the thymus, particularly the atrophied thymus, was able to harbor blood stream-circulating melanoma cells. Using specific in vivo + in vitro technique, where thymuses of doxorubicin- or PBS-treated mice are co-cultured with doxorubicin-treated melanoma cells in trans-well system we want to provide the insight of the changes in the status of cancer cells.

Results: We found that chemotherapy-resulted DNA-damage response triggered p53 activation in non-malignant thymic cells, which in turn resulted in thymocyte death and thymic epithelial cell senescence to develop an inflammatory thymic microenvironment. Co-culture of PBS- or Doxo- treated thymus with Doxo-treated melanoma cells provides evidence that chemotherapy-altered inflammatory thymic microenvironment protects cancer cells from apoptosis via induction of dormancy.

Conclusion: Therefore, the thymus, which becomes a pre-metastatic reservoir for non-lymphoid solid tumor cells under chemotherapy, should be a novel target in antitumor therapy for considering and preventing from tumor metastatic relapse.